Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Status:
Terminated
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for
the prevention of thromboembolic events during induction therapy in transplant-eligible
patients with newly diagnosed multiple myeloma who receive bortezomib, thalidomide, and
dexamethasone (VTD) during the induction phase of therapy prior to autologous stem cell
transplantation (ASCT). The current study is designed to evaluate the efficacy and safety of
apixaban during the induction period. Efficacy will be defined as a composite endpoint of
acute symptomatic proximal and distal deep venous thrombosis, pulmonary embolism, VTE related
deaths, and acute ischemic stroke.